Rate of Antigen Degradation by the Ubiquitin-proteasome Pathway Influences MHC Class I Presentation
Overview
Authors
Affiliations
The effect on MHC class I Ag presentation of enhancing a protein's rate of degradation by the ubiquitin-proteasome pathway was investigated. In extracts of mouse B-lymphoblasts and reticulocytes, as in rabbit reticulocytes, proteins with acidic or basic N-termini are conjugated to ubiquitin and degraded by the 26S proteasome very rapidly. We found that the rate of MHC class I presentation of microinjected beta-galactosidase was enhanced when this antigenic protein was modified with such a destabilizing amino-terminal residue. This enhanced presentation was inhibited by blocking potential ubiquitination sites on the protein through methylation of amino groups and by peptide aldehyde inhibitors of the proteasome. Furthermore, in B lymphoblast cell extracts, the rapid degradation of these beta-galactosidase constructs required ATP and ubiquitin and was blocked by inhibitors of proteasomes. Their rates of degradation in extracts correlated with their rates of class I Ag presentation in vivo. These results indicate that ubiquitin conjugation is a key rate-limiting step in Ag presentation and provide further evidence for a critical role of ubiquitin and the 26S proteasome in generating MHC class I-presented peptides.
Rab8a restores diverse innate functions in CD11cCD11b dendritic cells from aged mice.
Singh S, Tehseen A, Dahiya S, Singh Y, Sarkar R, Sehrawat S Nat Commun. 2024; 15(1):10300.
PMID: 39604443 PMC: 11603169. DOI: 10.1038/s41467-024-54757-2.
Inhibiting UCH-L5: Rational Design of a Cyclic Ubiquitin-Based Peptide Inhibitor.
Hameed D, Ovaa H, van der Heden van Noort G, Sapmaz A Front Mol Biosci. 2022; 9:866467.
PMID: 35720124 PMC: 9204298. DOI: 10.3389/fmolb.2022.866467.
Interferon-stimulated gene products as regulators of central carbon metabolism.
Ebrahimi K, Gilbert-Jaramillo J, James W, McCullagh J FEBS J. 2020; 288(12):3715-3726.
PMID: 33185982 PMC: 8359365. DOI: 10.1111/febs.15625.
Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.
Cheng M, Farmer E, Huang C, Lin J, Hung C, Wu T Hum Gene Ther. 2018; 29(9):971-996.
PMID: 29316817 PMC: 6152857. DOI: 10.1089/hum.2017.197.
Setz C, Friedrich M, Rauch P, Fraedrich K, Matthaei A, Traxdorf M Viruses. 2017; 9(8).
PMID: 28805676 PMC: 5580479. DOI: 10.3390/v9080222.